Literature DB >> 21393145

Low incidence of renal impairment observed in tenofovir-treated patients.

E Paul O'Donnell1, Kimberly K Scarsi, Kristin M Darin, Lana Gerzenshtein, Michael J Postelnick, Frank J Palella.   

Abstract

OBJECTIVES: To compare the incidence of renal impairment in HIV-infected patients exposed versus unexposed to tenofovir and to characterize risk factors associated with renal impairment.
METHODS: We undertook a retrospective cohort and nested case-control study of 514 Northwestern University HIV Outpatient Study participants who received antiretroviral therapy (ART) between 1 August 2001 and 31 July 2007. Renal impairment was defined as meeting at least one of two validated criteria based on serum creatinine, calculated glomerular filtration rate and creatinine clearance. Multivariable analysis was performed to identify risk factors for renal impairment.
RESULTS: Renal impairment occurred in 14% (n = 72) of the cohort and was not correlated with exposure to tenofovir in univariate analyses. In multivariable analysis, more advanced age [odds ratio (OR) = 1.04, P = 0.02], diabetes (OR = 3.6, P < 0.01), decreased weight (OR = 0.97, P = 0.02) and endpoint CD4 ≤200 cells/mm(3) (OR = 2.5, P = 0.03) were positive predictors of renal impairment; tenofovir exposure (OR = 0.41, P = 0.01) was negatively correlated with renal impairment.
CONCLUSIONS: Tenofovir-containing ART was associated with less renal impairment than ART without tenofovir in a patient cohort with a high incidence of renal impairment. Chronic co-morbid conditions known to be associated with renal impairment should be excluded prior to attributing renal impairment to tenofovir.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21393145     DOI: 10.1093/jac/dkr039

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Susan L Koletar; Richard Moore; W Christopher Mathews; Heidi M Crane; Kenneth Mayer; Anne Zinski; James S Kahn; Joseph J Eron
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

2.  Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Authors:  Samir K Gupta; Albert M Anderson; Ramin Ebrahimi; Todd Fralich; Hiba Graham; Valeska Scharen-Guivel; John F Flaherty; Claude Fortin; Robert C Kalayjian; Anita Rachlis; Christina M Wyatt
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

3.  Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?

Authors:  Jasmine R Marcelin; Melody L Berg; Eugene M Tan; Hatem Amer; Nathan W Cummins; Stacey A Rizza
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

4.  Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.

Authors:  Reneé De Waal; Karen Cohen; Matthew P Fox; Kathryn Stinson; Gary Maartens; Andrew Boulle; Ehimario U Igumbor; Mary-Ann Davies
Journal:  J Int AIDS Soc       Date:  2017-04-10       Impact factor: 5.396

5.  Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.

Authors:  Anna Bonjoch; Patricia Echeverría; Núria Perez-Alvarez; Jordi Puig; Carla Estany; Bonaventura Clotet; Eugènia Negredo
Journal:  Biomed Res Int       Date:  2016-12-18       Impact factor: 3.411

6.  Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.

Authors:  Oche O Agbaji; Isaac O Abah; Augustine O Ebonyi; Zumnan M Gimba; Esla E Abene; Simji S Gomerep; Kakjing D Falang; Joseph Anejo-Okopi; Patricia A Agaba; Placid O Ugoagwu; Emmanuel I Agaba; Godwin E Imade; Atiene S Sagay; Prosper Okonkwo; John A Idoko; Phyllis J Kanki
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec

7.  Factors Associated with Antiretroviral Therapy Toxicity Out-Comes in Patients with and without Hypertension.

Authors:  Sabelo Bonginkosi Dlamini; Ming-Tsang Wu; Hans-Uwe Dahms
Journal:  Int J Environ Res Public Health       Date:  2022-09-03       Impact factor: 4.614

8.  Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients.

Authors:  Bazim V Ojeh; Isaac O Abah; Placid Ugoagwu; Patricia A Agaba; Oche O Agbaji; Steven S Gyang
Journal:  Germs       Date:  2018-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.